HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy.
Fauquembergue E, Toutirais O, Tougeron D, Drouet A, Le Gallo M, Desille M, Cabillic F, de La Pintière CT, Iero M, Rivoltini L, Baert-Desurmont S, Leprince J, Vaudry H, Sesboué R, Frébourg T, Latouche JB, Catros V.
Fauquembergue E, et al. Among authors: latouche jb.
J Immunother. 2010 May;33(4):402-13. doi: 10.1097/CJI.0b013e3181d366da.
J Immunother. 2010.
PMID: 20386466